Drug susceptibility testing should be offered to all TB-infected people to ensure they are started on appropriate and effective treatment. Molecular tests, such as line probe assays (LPAs) are increasingly being used to rapidly diagnose TB and initiate appropriate treatment. The GLI Core Group, WHO Global TB Program, and the Supranational Reference Laboratory developed a guide to provide practical guidance for the interpretation of the most commonly used first and second line LPAs. This webinar discusses the use of the guide, including a review of basic concepts on mutation, resistance, and clinical practice implications; LPA advances; and interpretation on INH resistance and MFX resistance.
Click the video to view the webinar.